Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis.
CONCLUSIONS: CT-P13 was effective and safe in a real-life setting in patients with active RA or AS.
PMID: 29439591 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Allergy & Immunology | Ankylosing Spondylitis | Arthritis | Bulgaria Health | Czechia Health | Remicade | Research | Rheumatoid Arthritis | Rheumatology | Romania Health | Study